Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Non-small-cell lunG Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02400814
What this trial is testing

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Megan Daly, MD 27
Not applicableUnknownNCT02055144
What this trial is testing

Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy

Who this might be right for
Non Small Cell Lung Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 100
Early research (Phase 1)Ended earlyNCT03948763
What this trial is testing

MRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms+1 more
Merck Sharp & Dohme LLC 70
Large-scale testing (Phase 3)Looking for participantsNCT06345729
What this trial is testing

Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 600
Large-scale testing (Phase 3)Looking for participantsNCT06838273
What this trial is testing

BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 720
Testing effectiveness (Phase 2)Study completedNCT01951586
What this trial is testing

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Amgen 226
Testing effectiveness (Phase 2)Ended earlyNCT04424641
What this trial is testing

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumor(s)Prostate CancerEsophageal Cancer+5 more
Genmab 48
Early research (Phase 1)Ended earlyNCT02346370
What this trial is testing

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Halozyme Therapeutics 16
Testing effectiveness (Phase 2)Study completedNCT00004139
What this trial is testing

Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
Alliance for Clinical Trials in Oncology 80
Not applicableStudy completedNCT00899028
What this trial is testing

Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Who this might be right for
Lung Cancer
Vanderbilt University Medical Center 689
Early research (Phase 1)WithdrawnNCT02451865
What this trial is testing

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT04452877
What this trial is testing

Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 40
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Not applicableApproved For MarketingNCT06279728
What this trial is testing

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Who this might be right for
EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT01378962
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT00271505
What this trial is testing

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 43
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685197
What this trial is testing

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

Who this might be right for
NSCLCEGFR Activating MutationEGFR-TKI-resistant Non-Small Cell Lung Cancer+2 more
Zhou Chengzhi 100
Post-approval studies (Phase 4)Study completedNCT02316327
What this trial is testing

Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Fundacion Clinic per a la Recerca Biomédica 19
Testing effectiveness (Phase 2)UnknownNCT05141786
What this trial is testing

MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Who this might be right for
Non-small- Cell Lung Cancer (NSCLC)
Shanghai Miracogen Inc. 100
Next Page